Cencora (NYSE:COR) reported a 7.5% increase in adjusted diluted EPS to $4.75 for the second quarter of fiscal 2026, amid a consolidated revenue rise of 4% to $78.4 billion. However, the company lowered its full-year revenue growth guidance from 7%-9% to 4%-6% due to faster-than-expected brand conversions at a major customer and slower growth in GLP-1 products. Cencora’s operating income increased by 6% to $1.3 billion.
Management also raised its full-year adjusted EPS outlook to $17.65-$17.90, up from $17.45-$17.75. The U.S. Healthcare Solutions segment saw a revenue increase of 3% to $68.8 billion, despite challenges from customer losses and product price reductions. Conversely, the International Healthcare Solutions segment experienced a 13% revenue rise to $7.6 billion, bolstered by European distribution growth.
Cencora ended the quarter with $2.2 billion in cash and generated $1.1 billion in free cash flow. The company plans to resume opportunistic share repurchases, intending to buy back $1 billion of shares by year-end.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
